AWM
BTAI icon

AllSquare Wealth Management’s BioXcel Therapeutics BTAI Stock Holding History

AllSquare Wealth Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$448 Hold
175
– – ﹤0.01% 504
2025
Q2 		$317 Hold
175
– – ﹤0.01% 509
2025
Q1 		$355 Buy
+175
New +$653 ﹤0.01% 508
2024
Q4 		– Sell
-283
Closed -$2.76K – 542
2024
Q3 		$2.76K Hold
283
– – ﹤0.01% 458
2024
Q2 		$5.79K Hold
283
– – ﹤0.01% 417
2024
Q1 		$12.8K Hold
283
– – 0.01% 354
2023
Q4 		$13.4K Hold
283
– – 0.01% 344
2023
Q3 		$11.5K Sell
283
-62
-18% -$6.27K 0.01% 357
2023
Q2 		$105K Hold
345
– – 0.07% 131
2023
Q1 		$103K Hold
345
– – 0.07% 137
2022
Q4 		$119K Hold
345
– – 0.08% 123
2022
Q3 		$65K Hold
345
– – 0.05% 162
2022
Q2 		$73K Buy
345
+147
+74% +$30.9K 0.05% 162
2022
Q1 		$66K Hold
198
– – 0.04% 185
2021
Q4 		$64K Sell
198
-136
-41% -$58.4K 0.04% 191
2021
Q3 		$162K Sell
334
-4
-1% -$1.76K 0.1% 110
2021
Q2 		$157K Sell
338
-28
-8% -$15.3K 0.09% 116
2021
Q1 		$253K Buy
366
+23
+7% +$18.5K 0.16% 81
2020
Q4 		$254K Buy
343
+255
+290% +$199K 0.17% 74
2020
Q3 		$61K Buy
+88
New +$66.1K 0.04% 171
2020
Q2 		– Sell
-61
Closed -$22K – 465
2020
Q1 		$22K Sell
61
-52
-46% -$18.7K 0.02% 240
2019
Q4 		$26K Sell
113
-75
-40% -$7.54K 0.02% 241
2019
Q3 		$21K Buy
188
+79
+72% +$12.5K 0.02% 254
2019
Q2 		$19K Hold
109
– – 0.01% 267
2019
Q1 		$17K Buy
+109
New +$13.4K 0.01% 266

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

AllSquare Wealth Management's BTAI Position: Q3 2025 in Review

AllSquare Wealth Management held its BioXcel Therapeutics (BTAI) position steady in Q3 2025 at 175 shares worth $448. The position accounts for ﹤0.01% of the portfolio, ranked #504.

AllSquare Wealth Management first reported a position in BTAI in Q1 2019 and has held it in 25 quarters since. The position peaked at $254K in Q4 2020. 35 funds tracked by Wall St. Rank hold BTAI as of Q3 2025.

  • AllSquare Wealth Management held 175 shares of BioXcel Therapeutics worth $448 as of Q3 2025.
  • AllSquare Wealth Management left its BioXcel Therapeutics share count unchanged in Q3 2025.
  • BioXcel Therapeutics made up ﹤0.01% of AllSquare Wealth Management's portfolio in Q3 2025, its #504 holding.
  • AllSquare Wealth Management first reported a position in BioXcel Therapeutics in Q1 2019 and has held it in 25 quarters since.
  • AllSquare Wealth Management's BioXcel Therapeutics position peaked at $254K in Q4 2020.
  • 35 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2025.

Based on AllSquare Wealth Management's 13F filing for Q3 2025, filed 12 Jan 2026.